Summary
55 / 100 · Bulios Score
What speaks for it
- Revenue grew by 46% a year over the last 3 years.
- The price moves less than the market (beta 0.39).
What to watch
- It passes only 2 of the 9 points of the Piotroski financial health test.
- For every 100 USD of bills due within a year it has 0.2 USD of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
Revenue grew by 46% a year over the last 3 years.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $1.02M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Corporate Segment 100%
- Other Member 0.4%
By region
- SINGAPORE 64%
- HONG KONG 25%
- MALAYSIA 6.1%
- THAILAND 3.6%
- CHINA 0.9%
- Other 0.2%
Corporate Segment brings in 100% of revenue.
Segments in detail